Potent inhibitors of CYP1A2 are expected to increase
duloxetine levels. This has been
seen with
fluvoxamine (see below) and is predicted to occur with
quinolones (e.g.
ciprofloxacin and enoxacin).
The manufacturer advises that concurrent use should be avoided. Note that the
quinolones may interact to varying extents, see
quinolones.